Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Macrocyclic inhibitors of hepatitis C virus|
|Abstract:||Inhibitors of HCV replication of formula (I) ##STR00001## and the N-oxides, salts, and stereoisomers, wherein each dashed line represents an optional double bond; X is N, CH and where X bears a double bond it is C; R.sup.1 is --OR.sup.7, --NH--SO.sub.2R.sup.8; R.sup.2 is hydrogen, and where X is C or CH, R.sup.2 may also be C.sub.1-6alkyl; R.sup.3 is hydrogen, C.sub.1-6alkyl, C.sub.3-7cycloalkyl; R.sup.4 is aryl or Het; n is 3, 4, 5, or 6; R.sup.5 is halo, C.sub.1-6alkyl, hydroxy, C.sub.1-6alkoxy, phenyl, or Het; R.sup.6 is C.sub.1-6alkoxy, or dimethylamino; R.sup.7 is hydrogen; aryl; Het; C.sub.3-7cycloalkyl optionally substituted with C.sub.1-6alkyl; or C.sub.1-6alkyl optionally substituted with C.sub.3-7cycloalkyl, aryl or with Het; R.sup.8 is aryl; Het; C.sub.3-7cycloalkyl optionally substituted with C.sub.1-6alkyl; or C.sub.1-6alkyl optionally substituted with C.sub.3-7cycloalkyl, aryl or with Het; aryl is phenyl optionally substituted with one, two or three substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur, and being optionally substituted with one, two or three substituents; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.|
|Inventor(s):||Simmen; Kenneth Alan (Tervuren, BE), De Kock; Herman Augustinus (Arendonk, BE), Raboisson; Pierre Jean-Marie Bernard (Sterrebeek, BE), Nilsson; Karl Magnus (Huddinge, SE), Samuelsson; Bengt Bertil (Huddinge, SE), Rosenquist; .ANG.sa Annica Kristina (Huddinge, SE)|
|Assignee:||Tibotec Pharmaceuticals Ltd. (Eastgate, County Cork, IE) Medivar AB (Huddinge, SE)|
1. A compound of the formula: ##STR00194## or a pharmaceutically acceptable salt thereof or a stereochemically isomeric form thereof or a pharmaceutically acceptable
salt of the stereochemically isomeric form.
2. A compound of the formula: ##STR00195## or a pharmaceutically acceptable salt thereof.
3. The compound according to claim 2 in its pharmaceutically acceptable salt form.
4. The compound according to claim 3 wherein the pharmaceutically acceptable salt is an acid addition salt.
5. The compound according to claim 3 wherein the pharmaceutically acceptable salt is a base addition salt.
6. The compound according to claim 3 wherein the pharmaceutically acceptable salt is a hydrochloride acid addition salt.
7. The compound according to claim 3 wherein the pharmaceutically acceptable salt is a sodium addition salt.
8. The compound according to claim 2, which is stereochemically pure.
9. The compound according to claim 1 wherein the compound is a powder.
10. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier therefore.
11. A method of inhibiting HCV replication in a warm-blooded animal comprising administering to said animal in need thereof a therapeutically effective amount of a compound according to claim 1.
12. The method according to claim 11 wherein the warm-blooded animal is human.
13. The method according to claim 11 wherein the compound has the formula ##STR00196## or a pharmaceutically acceptable salt thereof.
14. A process of preparing a compound of the formula ##STR00197## which comprises reacting under effective conditions a compound of formula 46 ##STR00198## and cyclopropylsulfonamide.
15. The process according to claim 14 wherein the process comprises (a) stirring at reflux under nitrogen for 2 hours, a solution of 560 mg (0.867 mmol) of compound no. 46 and 308 mg (1.90 mmol) of carbonyldiimidazole in 10 mL of dry tetrahydrofuran; (b) cooling the reaction mixture obtainable from step a) to room temperature and adding 400 mg (3.301 mmol) of cyclopropylsulfonamide and 286 mg of DBU (1.881 mmol); (c) heating the solution obtainable from step b) at 50.degree. C. for 15 hours; (d) cooling down the reaction mixture obtainable from step c) at room temperature and concentrating it under reduced pressure; (e) partitioning the residue obtainable from step d) between CH.sub.2Cl.sub.2 and HCl 1 N, washing the organic layer with brine, drying said organic layer with MgSO.sub.4, and evaporating said organic layer; (f) purifying the organic layer obtainable from step e) by flash chromatography (gradient of EtOAc (0 to 25%) in CH.sub.2Cl.sub.2) affording 314 mg of an off-white solid; and (g) washing the off-white solid obtainable from step f) with water and then with isopropyl ether, and drying said off-white solid in a vacuum oven.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.